JP2022547081A5 - - Google Patents
Info
- Publication number
- JP2022547081A5 JP2022547081A5 JP2022514681A JP2022514681A JP2022547081A5 JP 2022547081 A5 JP2022547081 A5 JP 2022547081A5 JP 2022514681 A JP2022514681 A JP 2022514681A JP 2022514681 A JP2022514681 A JP 2022514681A JP 2022547081 A5 JP2022547081 A5 JP 2022547081A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- cells
- patient
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896908P | 2019-09-06 | 2019-09-06 | |
| US62/896,908 | 2019-09-06 | ||
| PCT/EP2020/074804 WO2021044005A1 (en) | 2019-09-06 | 2020-09-04 | Anti-cd73 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547081A JP2022547081A (ja) | 2022-11-10 |
| JP2022547081A5 true JP2022547081A5 (https=) | 2023-09-08 |
| JP7662617B2 JP7662617B2 (ja) | 2025-04-15 |
Family
ID=72517218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514681A Active JP7662617B2 (ja) | 2019-09-06 | 2020-09-04 | 抗ｃｄ７３抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11634500B2 (https=) |
| EP (1) | EP4025605A1 (https=) |
| JP (1) | JP7662617B2 (https=) |
| KR (1) | KR20220057558A (https=) |
| CN (1) | CN115023439B (https=) |
| AU (1) | AU2020342778A1 (https=) |
| BR (1) | BR112022003956A2 (https=) |
| CA (1) | CA3153213A1 (https=) |
| CL (1) | CL2024002093A1 (https=) |
| CO (1) | CO2022002622A2 (https=) |
| IL (1) | IL291068A (https=) |
| MX (1) | MX2022002682A (https=) |
| MY (1) | MY207784A (https=) |
| PE (1) | PE20220708A1 (https=) |
| PH (1) | PH12022550509A1 (https=) |
| TW (1) | TWI859319B (https=) |
| UA (1) | UA130408C2 (https=) |
| WO (1) | WO2021044005A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221409A1 (es) | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| JP2023532234A (ja) * | 2020-06-22 | 2023-07-27 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｃｄ７３抗体とその用途 |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| CN117304316A (zh) * | 2022-06-22 | 2023-12-29 | 复旦大学 | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116178546B (zh) * | 2022-10-13 | 2024-06-18 | 深圳市百士通科技开发有限公司 | 一种多功能重组抗体及其制备方法和应用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025135233A1 (ko) * | 2023-12-21 | 2025-06-26 | ㈜지아이이노베이션 | Cd73에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US338841A (en) | 1886-03-30 | herden | ||
| US256055A (en) | 1882-04-04 | Compound engine | ||
| US323997A (en) | 1885-08-11 | Machine-gun | ||
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AU2001259142C1 (en) | 2000-04-25 | 2006-11-23 | Biogen Idec Inc. | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| EP1613350B1 (en) | 2003-04-09 | 2009-03-18 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
| WO2006113181A2 (en) | 2005-04-08 | 2006-10-26 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
| WO2006125140A2 (en) | 2005-05-18 | 2006-11-23 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
| US8975081B2 (en) | 2007-10-24 | 2015-03-10 | Faron Pharmaceuticals Oy | Biomarker for monitoring development of diseases and assessing the efficacy of therapies |
| EP2593595B1 (en) * | 2010-07-16 | 2020-03-11 | Avantgen, Inc. | Novel peptides and uses thereof |
| WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| JP2017514458A (ja) * | 2014-03-12 | 2017-06-08 | プロセナ バイオサイエンシーズ リミテッド | Ｌｇ４−５に対して特異的な抗−ラミニン４抗体 |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| EP3204417B1 (en) | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| CA2988119A1 (en) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| ES2924402T3 (es) | 2015-10-02 | 2022-10-06 | Symphogen As | Anticuerpos anti-PD-1 y composiciones |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CN114805575B (zh) | 2015-12-09 | 2024-07-23 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| US20200232974A1 (en) | 2016-03-30 | 2020-07-23 | Centre Léon-Bérard | Lymphocytes expressing cd73 in cancerous patient dictates therapy |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| PH12019500668B1 (en) * | 2016-10-13 | 2023-12-06 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-lag-3 antibodies and compositions |
| CA3045376C (en) | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| US20210107989A1 (en) | 2017-04-04 | 2021-04-15 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| US11530273B2 (en) | 2017-05-23 | 2022-12-20 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019173692A2 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
-
2020
- 2020-09-04 UA UAA202201023A patent/UA130408C2/uk unknown
- 2020-09-04 EP EP20772002.0A patent/EP4025605A1/en active Pending
- 2020-09-04 WO PCT/EP2020/074804 patent/WO2021044005A1/en not_active Ceased
- 2020-09-04 CN CN202080076881.9A patent/CN115023439B/zh active Active
- 2020-09-04 KR KR1020227010511A patent/KR20220057558A/ko active Pending
- 2020-09-04 AU AU2020342778A patent/AU2020342778A1/en active Pending
- 2020-09-04 PE PE2022000364A patent/PE20220708A1/es unknown
- 2020-09-04 MY MYPI2022001106A patent/MY207784A/en unknown
- 2020-09-04 US US17/012,942 patent/US11634500B2/en active Active
- 2020-09-04 CA CA3153213A patent/CA3153213A1/en active Pending
- 2020-09-04 PH PH1/2022/550509A patent/PH12022550509A1/en unknown
- 2020-09-04 BR BR112022003956A patent/BR112022003956A2/pt unknown
- 2020-09-04 MX MX2022002682A patent/MX2022002682A/es unknown
- 2020-09-04 TW TW109130508A patent/TWI859319B/zh active
- 2020-09-04 JP JP2022514681A patent/JP7662617B2/ja active Active
-
2022
- 2022-03-02 IL IL291068A patent/IL291068A/en unknown
- 2022-03-04 CO CONC2022/0002622A patent/CO2022002622A2/es unknown
-
2023
- 2023-03-17 US US18/185,848 patent/US20230227573A1/en active Pending
-
2024
- 2024-07-10 CL CL2024002093A patent/CL2024002093A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547081A5 (https=) | ||
| CN111936164B (zh) | 癌的治疗和/或预防用药物组合物 | |
| JP2024527606A5 (https=) | ||
| JP7797875B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP2024109885A (ja) | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 | |
| WO2016187220A2 (en) | Anti-ror1 antibodies | |
| JP2025166117A (ja) | 腫瘍性疾患のための治療 | |
| JP2017518958A (ja) | 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用 | |
| CN116615250A (zh) | 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗 | |
| CN114761433B (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| TW202210519A (zh) | 抗ｃ－Ｍｅｔ抗體藥物偶聯物及其應用 | |
| JP2023522630A5 (https=) | ||
| WO2022237666A1 (zh) | 一种抗Claudin18.2抗体及其抗体药物偶联物 | |
| EP2710038B1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| Mendelsohn | Jeremiah Metzger Lecture. Targeted cancer therapy | |
| JP7715041B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP7793986B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP7793985B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| NZ785824A (en) | Anti-cd73 antibodies | |
| NZ785824B2 (en) | Anti-cd73 antibodies | |
| WO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| EP4681780A1 (en) | Immunocytokine for cancer treatment | |
| JP7848119B2 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ | |
| TWI920018B (zh) | 抗ｈｅｒ３抗體-藥物結合物用於治療ｈｅｒ３突變癌之醫藥的用途 | |
| US11198733B2 (en) | Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor |